Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saumil Oza

Clinical Cardiac Electrophysiology Jacksonville, FL Medical Doctor

NPI 1962587014 CMS profile 362146

1824 King Street, Suite 300, Jacksonville, FL 32204

Open in the dashboard

General payments

$462,132

649 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,595,512 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Saumil Oza of Jacksonville, FL is reported in the CMS Open Payments database as having received $462,132 across 649 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,595,512 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $73,438 91
2024 General $221,846 147
2023 General $86,906 110
2022 General $49,531 127
2021 General $11,295 52
2020 General $5,160 16
2019 General $13,955 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saumil Oza
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Saumil Oza were reported at $73,438. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Saumil Oza Clinical Cardiac Electrophysiology median Middle half National median
2019 $13,955 $2,361 $585–$8,260 $163
2020 $5,160 $993 $247–$4,351 $114
2021 $11,295 $1,185 $326–$4,739 $132
2022 $49,531 $2,073 $554–$6,789 $149
2023 $86,906 $2,568 $759–$8,159 $160
2024 $221,846 $2,557 $703–$7,403 $164
2025 $73,438 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $100,551 172 payments
  2. Biosense Webster, Inc. $98,112 165 payments
  3. Medical Device Business Services, Inc. $83,499 55 payments
  4. Acarix USA Inc. $83,400 1 payment
  5. Volta Medical Inc $46,097 35 payments
  6. Atricure, Inc. $23,668 49 payments
  7. Ge Healthcare $7,820 8 payments
  8. Novo Nordisk Inc $5,750 9 payments
  9. Siemens Medical Solutions USA, Inc. $3,626 2 payments
  10. AltaThera Pharmaceuticals LLC $3,022 4 payments
  11. Other $6,587 149 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $338,429 103 payments
  2. Travel and Lodging $73,377 109 payments
  3. Food and Beverage $24,929 420 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,275 7 payments
  5. Honoraria $5,122 10 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $164,482 167 payments
  2. CADScor System $83,400 1 payment
  3. VX1 Cardiovascular $39,224 28 payments
  4. WATCHMAN Access System $30,521 55 payments
  5. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $16,419 26 payments
  6. Carto 3 System $14,095 22 payments
  7. General - Therapies $10,912 13 payments
  8. WATCHMAN FLX $9,446 11 payments
  9. FARAPULSE $5,707 5 payments
  10. VX1 Cardiovascular $5,498 6 payments
  11. Other $35,713 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,528

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$665,358

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

50.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 497 $514,579
Xarelto Rivaroxaban Brand 62 $75,709
Multaq Dronedarone Hcl Brand 24 $26,607
Entresto Sacubitril/Valsartan Brand 27 $25,784
Corlanor Ivabradine Hcl Brand 14 $9,338
Flecainide Acetate Generic 104 $3,513
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 44 $3,384
Metoprolol Succinate Generic 136 $1,566
Sotalol Sotalol Hcl Brand 62 $949
Amiodarone Hcl Generic 82 $894

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$475,113

Medicare's payments for the services billed

Medicare patients

1,050

Average age 78

Services billed

6,468

488 women, 562 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 57%
Arthritis 54%
Heart failure 46%
Diabetes 39%
Chronic kidney disease 37%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $1,200
$1,200 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

649 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record